Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Radiation Treatment After BCMA CAR-T Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate at 1 year and Duration of Response at 1 year. Started May 2022; status: active, not recruiting.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05336383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05336383.